Artificial Intelligence | Machine Learning | Machine Perception Renalytix AI | AI for Kidney Disease


Solutions for Kidney Disease, Healthcare, Medical Device, Health Diagnostics New York, NY, United States

Renalytix AI

Artificial Intelligence | Machine Learning | Machine Perception


Renalytix AI | AI for Kidney Disease

Renalytix AI

Solutions for Kidney Disease, Healthcare, Medical Device, Health Diagnostics


New York, NY, United States

Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. RenalytixAI’s initial diagnostic product, KidneyIntelX™, is designed to diagnose and improve clinical management of patients with Type II diabetes and those of African ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the U.S. healthcare system. RenalytixAI expects to commercially launch KidneyIntelX as a laboratory developed test in its CLIA laboratory facilities to health systems and drug developers in H2 2019.

 

B2C, B2B

26 to 50

Pre-IPO

$46.4M

Scaling Up

2018

 
 

Medical Devices
Managed Health Care
Health Care Facilities & Hospitals

N/A

Increase Efficiency

 
 

Analytics
IT and Security

Yes

Active

 
 

   Machine Learning
   Machine Perception


N/A


Image

Image

Video

Video

Semi-Structured

Semi-Structured

 

   Software


N/A


N/A

 
 
James McCullough


James McCullough
CEO

Fergus Fleming


Fergus Fleming
CTO

O. James Sterling


O. James Sterling
CFO

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Renalytix AI